• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Computer-aided design of magnetic molecularly imprinted polymer nanoparticles for solid-phase extraction and determination of levetiracetam in human plasma
【24h】

Computer-aided design of magnetic molecularly imprinted polymer nanoparticles for solid-phase extraction and determination of levetiracetam in human plasma

机译：固相萃取和测定人血浆中左乙拉西坦的磁性分子印迹聚合物纳米粒子的计算机辅助设计

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Analytical methods should be accurate and specific to measure plasma drug concentration. Nevertheless, current sample preparation techniques suffer from limitations, including matrix interference and intensive sample preparation. In this study, a novel technique was proposed for the synthesis of a molecularly imprinted polymer (MIP) on magnetic Fe _(3) O _(4) nanoparticles (NPs) with uniform core–shell structure. The Fe _(3) O _(4) @MIPs NPs were then applied to separate and enrich an antiepileptic drug, levetiracetam, from human plasma. A computational approach was developed to screen the functional monomers and polymerization solvents to provide a suitable design for the synthesized MIP. Different analysis techniques and re-binding experiments were performed to characterize the Fe _(3) O _(4) @MIP NPs, as well as to identify optimal conditions for the extraction process. Adsorption isotherms were best fitted to the Langmuir model and adsorption kinetics were modeled with pseudo-second-order kinetics. The Fe _(3) O _(4) @MIP NPs showed reasonable adsorption capacity and improved imprinting efficiency. A validated colorimetric assay was introduced as a comparable method to a validated HPLC assay for the quantitation of levetiracetam in plasma in the range of 10–80 μg mL ~(?1) after extraction. The results from the HPLC and colorimetric assays showed good precision (between 1.08% and 9.87%) and recoveries (between 94% and 106%) using the Fe _(3) O _(4) @MIP NPs. The limit of detection and limit of quantification were estimated to be 2.58 μg mL ~(?1) and 7.81 μg mL ~(?1) , respectively for HPLC assay and 2.32 μg mL ~(?1) and 7.02 μg mL ~(?1) , respectively for colorimetric assay. It is believed that synthesized Fe _(3) O _(4) @MIP NPs as a sample clean-up technique combined with the proposed assays can be used for determination of levetiracetam in plasma.
机译：分析方法应准确且特定于血浆药物浓度的测量。然而，当前的样品制备技术存在局限性，包括基质干扰和密集的样品制备。在这项研究中，提出了一种新颖的技术，用于在具有均匀核壳结构的磁性Fe _（3）O _（4）纳米颗粒（NPs）上合成分子印迹聚合物（MIP）。然后将Fe_（3）O_（4）@MIPs NP用于从人血浆中分离和富集抗癫痫药左乙拉西坦。开发了一种计算方法来筛选功能单体和聚合溶剂，以为合成的MIP提供合适的设计。进行了不同的分析技术和重新结合实验，以表征Fe _（3）O _（4）@MIP NP，以及确定提取过程的最佳条件。吸附等温线最适合Langmuir模型，吸附动力学用伪二级动力学建模。 Fe _（3）O _（4）@MIP NPs表现出合理的吸附能力并提高了印迹效率。引入了一种经过验证的比色测定法，作为一种经过验证的HPLC测定法的可比方法，用于定量提取后血浆中左乙拉西坦的浓度范围为10–80μgmL〜（？1）。 HPLC和比色测定的结果表明，使用Fe _（3）O _（4）@MIP NPs可以实现良好的精密度（1.08％至9.87％之间）和回收率（94％至106％之间）。 HPLC测定的检出限和定量限分别为2.58μgmL〜（？1）和7.81μgmL〜（？1），以及2.32μgmL〜（？1）和7.02μgmL〜（？ 1），分别用于比色法。可以认为，将合成的Fe _（3）O _（4）@MIP NPs作为样品净化技术，结合所提出的测定方法，可用于测定血浆中的左乙拉西坦。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号